Market Research NewsNews

Global Iron-Deficiency Anemia Therapy Market 2024: Global Key Players Apotex Inc, Luitpold Pharmaceuticals Inc, AMAG Pharmaceuticals, Acceleron Pharma, Inc., Bayer AG, Akebia Therapeutics, Inc., PHARMACOSMOS A/S

Market Definition:Iron deficiency anemia is a type of disease leading the deficiency of iron in the body which is caused by the unhealthy red blood cells. Red blood cells (RBCs) provide oxygen in the body tissue and iron plays significant role in preparing the hemoglobin, a common part of RBCs, and lack of iron produces less hemoglobin and less oxygen supply in the body.

Market Analysis: The Global Iron-Deficiency Anemia Therapy Market is expected to rise from its initial estimated value of USD 2.33 billion in 2018 to an estimated value of USD 4.67 billion by 2026 registering a CAGR of 9.1% in the forecast period of 2019-2026. This rise in the market can be attributed to the rising cases of Haemodilution in pregnancy and prevalence of Anemia.

Get Exclusive Sample Report: @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-iron-deficiency-anemia-therapy-market

Key Market Competitors: 

Few of the major market competitors currently working in the iron-deficiency anemia therapy market are Apotex Inc, Luitpold Pharmaceuticals Inc, AMAG Pharmaceuticals, Acceleron Pharma, Inc., Bayer AG, Akebia Therapeutics, Inc., PHARMACOSMOS A/S, Allergen, Keryx Biopharmaceuticals Inc., Johnson & Johnson Services, Luitpold Pharmaceuticals Inc., PIERIS, Cirondrugs, Salveo Lifecare,  .

Global Iron-Deficiency Anemia Therapy Market, By Type of Therapy (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion, Others), End User (Hospitals, Clinics, Home Healthcare), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)–Industry Trends & Forecast to 2026

Key Developments in the Market:

  • In November 2017, Keryx Biopharmaceuticals, Inc (U.S.) announced the U.S. FDA approval of drug for iron deficiency anemia Auryxia, used in the treatment of ron deficiency anemia in adults with chronic kidney disease (CKD) not suitable for patient on dialysis.
  • In February, AMAG Pharmaceuticals (U.S.) announced the U.S. FDA approval of Feraheme (ferumoxytol injection), which will be available for adults patients suffering from iron deficiency anemia and are intolerance to the oral iron.

Table of Contents

1. Introduction
2. Market Segmentation
3. Market Overview
4. Executive Summary
5. Premium Insights
6. Global, By Component
7. Product Type
8. Delivery
9. Industry Type
10. Geography
10.1. Overview
10.2. North America
10.3. Europe
10.4. Asia-Pacific
10.5. South America
10.6. Middle East & Africa
11. Company Landscape
12. Company Profiles
13. Related Reports

Request Complete TOC Of this Report @  https://databridgemarketresearch.com/toc/?dbmr=global-iron-deficiency-anemia-therapy-market

Market Drivers:

  • Rising cases of haemodilution in Pregnancy leading the growth of the market
  • High prevalence of anemia amongst the population fueling the market in the forecast period

Market Restraints:

  • Adverse effect of the therapy
  • Stringent regulatory guidelines for product approval

Segmentation: Global Iron-Deficiency Anemia Therapy Market 

  • By Type of Therapy
    • Oral Iron Therapy
    • Parenteral Iron Therapy
    • Red Blood Cell Transfusion
    • Others
  • By End-User
    • Hospitals
    • Clinics
    • Home Healthcare
  • By Geography
    • North America
      • US
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Rest of South America
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Russia
      • Turkey
      • Belgium
      • Netherlands
      • Switzerland
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • South Korea
      • India
      • Australia
      • Singapore
      • Malaysia
      • Indonesia
      • Thailand
      • Philippines
      • Rest of Asia-Pacific
    • Middle East and Africa
      • South Africa
      • Egypt
      • Saudi Arabia
      • United Arab Emirates
      • Israel
      • Rest of Middle East and Africa

Competitive Analysis: Global Iron-Deficiency Anemia Therapy Market 

The global iron-deficiency anemia therapy market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of iron-deficiency anemia therapy market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Grab Your Report at an Impressive Discount! Please click Here@ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-iron-deficiency-anemia-therapy-market

 

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

 

 

Tags

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close